TrialInternational immunopharmacology2020

Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial.

Reza Malekzadeh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.